INmune BioINMB
INMB
About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Employees: 13
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
100% more call options, than puts
Call options by funds: $3.07M | Put options by funds: $1.54M
61% more capital invested
Capital invested by funds: $28.8M [Q4 2024] → $46.3M (+$17.5M) [Q1 2025]
13% more funds holding
Funds holding: 71 [Q4 2024] → 80 (+9) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
1.98% less ownership
Funds ownership: 27.83% [Q4 2024] → 25.85% (-1.98%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for INMB.
Financial journalist opinion
Positive
Seeking Alpha
1 month ago
INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity
I rate INmune Bio, Inc. a speculative Strong Buy for high-risk investors, hinging on XPro's upcoming Phase II results in early Alzheimer's disease. XPro's unique mechanism targets neuroinflammation without ARIA risk, potentially serving 70% of early AD patients and outperforming current therapies. INMB's short cash runway makes positive XPro data critical for future funding, partnerships, or acquisition; failure could force shareholder dilution.
Neutral
Seeking Alpha
1 month ago
INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. Mark Lowdell - Chief Scientific Officer Dr. CJ Barnum - Head, Neuroscience Conference Call Participants Denis Reznik - Raymond James George Farmer - Scotiabank Tom Shrader - BTIG Laura Suriel - Alliance Global Partners Operator Greetings. And welcome to the INmune Bio First Quarter 2025 Earnings Call.
Neutral
GlobeNewsWire
1 month ago
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update.
Neutral
GlobeNewsWire
1 month ago
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 8th, 2025 at 4:30pm EDT to discuss results for its quarter ended March 31, 2025 and to provide a corporate update.
Neutral
GlobeNewsWire
2 months ago
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK.
Neutral
Seeking Alpha
2 months ago
INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer Christopher Barnum - Head of Neuroscience Conference Call Participants George Farmer - Scotiabank Thomas Shrader - BTIG Denis Reznik - Raymond James Elemer Piros - Rodman James Molloy - Alliance Global Partners Operator Greetings, and welcome to the INmune Bio's. 2024 Fourth Quarter and Full Year Earnings Call.
Neutral
GlobeNewsWire
2 months ago
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update.
Neutral
Seeking Alpha
2 months ago
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffett's increased stake, stable commodity prices, and promising long-term growth from a new Australian iron ore deal. Sandisk Corporation is also seen as a 'buy' post-separation from Western Digital, with strong market performance and potential for unlocking shareholder value as an independent flash storage company.
Positive
Seeking Alpha
2 months ago
INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results
INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billion valuation if successful, offering a 135x stock upside. CORDstrom may act as a fail-safe for INmune Bio's stock if XPro fails, ensuring a high likelihood of substantial returns.
Neutral
GlobeNewsWire
4 months ago
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.
Charts implemented using Lightweight Charts™